SI3964510T1 - Kristalna oblika WEE1 inhibitorske spojine in njena uporaba - Google Patents
Kristalna oblika WEE1 inhibitorske spojine in njena uporabaInfo
- Publication number
- SI3964510T1 SI3964510T1 SI202030468T SI202030468T SI3964510T1 SI 3964510 T1 SI3964510 T1 SI 3964510T1 SI 202030468 T SI202030468 T SI 202030468T SI 202030468 T SI202030468 T SI 202030468T SI 3964510 T1 SI3964510 T1 SI 3964510T1
- Authority
- SI
- Slovenia
- Prior art keywords
- crystal form
- inhibitor compound
- wee1 inhibitor
- wee1
- compound
- Prior art date
Links
- 101100102932 Xenopus laevis wee2-b gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910364694 | 2019-04-30 | ||
| PCT/CN2020/088451 WO2020221358A1 (zh) | 2019-04-30 | 2020-04-30 | Wee1抑制剂化合物的晶型及其应用 |
| EP20798924.5A EP3964510B1 (en) | 2019-04-30 | 2020-04-30 | Crystal form of wee1 inhibitor compound and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3964510T1 true SI3964510T1 (sl) | 2024-10-30 |
Family
ID=73029676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI202030468T SI3964510T1 (sl) | 2019-04-30 | 2020-04-30 | Kristalna oblika WEE1 inhibitorske spojine in njena uporaba |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12291536B2 (enExample) |
| EP (1) | EP3964510B1 (enExample) |
| JP (1) | JP7582970B2 (enExample) |
| CN (1) | CN113784968B (enExample) |
| AU (1) | AU2020266956B2 (enExample) |
| BR (1) | BR112021021230A8 (enExample) |
| CA (1) | CA3138240C (enExample) |
| DK (1) | DK3964510T3 (enExample) |
| ES (1) | ES2984617T3 (enExample) |
| FI (1) | FI3964510T3 (enExample) |
| HR (1) | HRP20241008T1 (enExample) |
| HU (1) | HUE068061T2 (enExample) |
| IL (1) | IL287472A (enExample) |
| LT (1) | LT3964510T (enExample) |
| PL (1) | PL3964510T3 (enExample) |
| PT (1) | PT3964510T (enExample) |
| RS (1) | RS65747B1 (enExample) |
| SG (1) | SG11202111315XA (enExample) |
| SI (1) | SI3964510T1 (enExample) |
| SM (1) | SMT202400303T1 (enExample) |
| WO (1) | WO2020221358A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| NZ598071A (en) * | 2006-10-27 | 2013-08-30 | Signal Pharm Llc | Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds |
| EP2155752B1 (en) * | 2007-04-25 | 2018-09-19 | Merck Sharp & Dohme Corp. | Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor |
| WO2009054332A1 (ja) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| PL2477628T3 (pl) | 2009-09-15 | 2015-02-27 | Merck Sharp & Dohme | Wytwarzanie krystalicznych hemihydratowych postaci dihydropirazolopirymidynonu |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| EP2731953A1 (en) | 2011-07-15 | 2014-05-21 | Abbvie Inc. | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| EP2776434A1 (en) | 2011-10-20 | 2014-09-17 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| MX2014010176A (es) | 2012-02-23 | 2014-11-10 | Abbvie Inc | Inhibidores de cinasas de piridopirimidinona. |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| CA3003737C (en) | 2015-11-01 | 2021-09-14 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of making and using the same |
| CN108623615B (zh) | 2017-03-23 | 2022-12-13 | 上海迪诺医药科技有限公司 | 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用 |
| JP7290638B2 (ja) | 2017-11-01 | 2023-06-13 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | Ｗｅｅ１阻害剤としての大環状化合物及びその使用 |
| EP3875460A4 (en) | 2018-10-26 | 2022-07-20 | Wuxi Biocity Biopharmaceutics Co., Ltd. | PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF |
-
2020
- 2020-04-30 PT PT207989245T patent/PT3964510T/pt unknown
- 2020-04-30 CN CN202080031816.4A patent/CN113784968B/zh active Active
- 2020-04-30 LT LTEPPCT/CN2020/088451T patent/LT3964510T/lt unknown
- 2020-04-30 RS RS20240816A patent/RS65747B1/sr unknown
- 2020-04-30 SG SG11202111315XA patent/SG11202111315XA/en unknown
- 2020-04-30 SI SI202030468T patent/SI3964510T1/sl unknown
- 2020-04-30 FI FIEP20798924.5T patent/FI3964510T3/fi active
- 2020-04-30 US US17/607,447 patent/US12291536B2/en active Active
- 2020-04-30 JP JP2021564588A patent/JP7582970B2/ja active Active
- 2020-04-30 ES ES20798924T patent/ES2984617T3/es active Active
- 2020-04-30 DK DK20798924.5T patent/DK3964510T3/da active
- 2020-04-30 BR BR112021021230A patent/BR112021021230A8/pt unknown
- 2020-04-30 HU HUE20798924A patent/HUE068061T2/hu unknown
- 2020-04-30 HR HRP20241008TT patent/HRP20241008T1/hr unknown
- 2020-04-30 AU AU2020266956A patent/AU2020266956B2/en active Active
- 2020-04-30 PL PL20798924.5T patent/PL3964510T3/pl unknown
- 2020-04-30 SM SM20240303T patent/SMT202400303T1/it unknown
- 2020-04-30 CA CA3138240A patent/CA3138240C/en active Active
- 2020-04-30 WO PCT/CN2020/088451 patent/WO2020221358A1/zh not_active Ceased
- 2020-04-30 EP EP20798924.5A patent/EP3964510B1/en active Active
-
2021
- 2021-10-21 IL IL287472A patent/IL287472A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12291536B2 (en) | 2025-05-06 |
| PL3964510T3 (pl) | 2024-08-19 |
| CA3138240A1 (en) | 2020-11-05 |
| AU2020266956A1 (en) | 2021-10-28 |
| JP2022530812A (ja) | 2022-07-01 |
| HUE068061T2 (hu) | 2024-12-28 |
| PT3964510T (pt) | 2024-07-29 |
| DK3964510T3 (da) | 2024-07-29 |
| ES2984617T3 (es) | 2024-10-30 |
| BR112021021230A8 (pt) | 2023-04-25 |
| EP3964510A4 (en) | 2023-04-26 |
| SG11202111315XA (en) | 2021-11-29 |
| IL287472A (en) | 2021-12-01 |
| LT3964510T (lt) | 2024-08-12 |
| SMT202400303T1 (it) | 2024-09-16 |
| HRP20241008T1 (hr) | 2024-11-08 |
| RS65747B1 (sr) | 2024-08-30 |
| FI3964510T3 (fi) | 2024-07-24 |
| JP7582970B2 (ja) | 2024-11-13 |
| BR112021021230A2 (enExample) | 2021-12-21 |
| EP3964510A1 (en) | 2022-03-09 |
| US20220220120A1 (en) | 2022-07-14 |
| EP3964510B1 (en) | 2024-07-03 |
| CN113784968A (zh) | 2021-12-10 |
| CA3138240C (en) | 2025-04-01 |
| WO2020221358A1 (zh) | 2020-11-05 |
| CN113784968B (zh) | 2024-03-15 |
| AU2020266956B2 (en) | 2025-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287472A (en) | Crystalline form of wee1 inhibitory compound and use thereof | |
| ZA202106511B (en) | Jak inhibitor compound and use thereof | |
| EP4056563A4 (en) | COMPOUND AS A SHP2 INHIBITOR AND USE THEREOF | |
| IL290106A (en) | A crystalline form of an atr inhibitor and its use | |
| EP3982949A4 (en) | MRSA1 INHIBITORS | |
| EP4349838A4 (en) | WEE1 INHIBITOR AND ITS USE | |
| SG11202109438TA (en) | A salt and crystal form of a fak inhibitor | |
| ZA202100923B (en) | Crystal form of lanosterol prodrug compound and application thereof | |
| ZA202109737B (en) | Compound used as kinase inhibitor and application thereof | |
| IL308476A (en) | Inhibitors of the menin-mil interaction | |
| IL276312A (en) | Use of Alkoxypyrazoles as nitrification inhibitors | |
| EP3774708A4 (en) | Foxm1 inhibitor compositions and methods of using the same | |
| EP4063366A4 (en) | CRYSTAL FORM OF NUCLEOPROTEIN INHIBITOR AND USE THEREOF | |
| IL285219A (en) | A crystal of the compound diarylthiohydantoin | |
| PL3670611T3 (pl) | Środek antykorozyjny do zabezpieczania wnęk i jego zastosowanie | |
| ZA202107810B (en) | Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof | |
| GB2589398B (en) | Compounds and methods of use | |
| ZA202101589B (en) | Crystal form of tri-cycle compound and application thereof | |
| IL291368A (en) | Inhibits expression of methadherin | |
| EP3845534A4 (en) | SALT FORM AND CRYSTALLINE FORM OF A NEW AZATRICYCLIC COMPOUND AND USE THEREOF | |
| EP3737945A4 (en) | NEW USE OF KIRREL2 AND A KIRREL2 INHIBITOR | |
| EP3957634A4 (en) | CRYSTALLINE FORM OF SGLT INHIBITOR AND ITS APPLICATION | |
| EP4023648A4 (en) | CARCINOGENIC FUSIONED KINASE HIBITOR CRYSTAL AND APPLICATIONS THEREOF | |
| HK40045217A (zh) | 激酶抑制剂化合物和组合物及使用方法 | |
| GB201908573D0 (en) | Compounds and methods of use |